Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial (vol 43, pg 465, 2024)

被引：0
|
作者：
Espay, A. J.
Stocchi, F.
Pahwa, R.
机构：
来源：
LANCET NEUROLOGY | 2024年 / 23卷 / 06期
关键词：
D O I：
10.1016/S1474-4422(24)00172-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：E10 / E10
页数：1
相关论文
共 50 条
  • [31] Efficacy of ND0612 a 24-hour Subcutaneous LevodopaCarbidopa Infusion for People with Parkinson's Disease Experiencing Motor Fluctuations: Subgroup-Analyses from a Randomized, Controlled Phase 3 Study
    Harrison, Antoinette
    Poewe, Werner
    Lopes, Nelson
    ANNALS OF NEUROLOGY, 2024, 96 : S219 - S220
  • [32] Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebocontrolled phase 3 trial (vol 18, pg 145, 2019)
    LeWitt, P. A.
    Hauser, R. A.
    Pahwa, R.
    LANCET NEUROLOGY, 2019, 18 (03): : E2 - E2
  • [33] Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial
    Hauser, Robert A.
    Olanow, C. Warren
    Kieburtz, Karl D.
    Pourcher, Emmanuelle
    Docu-Axelerad, Any
    Lew, Mark
    Kozyolkin, Olexandr
    Neale, Ann
    Resburg, Chris
    Meya, Uwe
    Kenney, Christopher
    Bandak, Stephen
    LANCET NEUROLOGY, 2014, 13 (08): : 767 - 776
  • [34] Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (vol 23, pg 393, 2024)
    Mercuri, E.
    Vilchez, J. J.
    Boespflug-Tanguy, O.
    LANCET NEUROLOGY, 2024, 23 (06): : E10 - E10
  • [35] The iNDiGO study: A multicenter, randomized, double-blind, placebo-controlled clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion given as adjunct treatment to oral levodopa in fluctuating PD
    Kieburtz, Karl
    Olanow, C. Warren
    Minei, Tami Rachmilewitz
    Cohen, Yael
    Oren, Sheila
    NEUROLOGY, 2018, 90
  • [36] A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients
    Li, Ying
    Zhu, Demei
    Sun, Shenghua
    Chang, Xiaoyue
    Cao, Zhaolong
    Yang, Yanping
    Fu, Xiuhua
    Li, Xiangyang
    Xu, Jinfu
    Zhu, Yingqun
    Hui, Fuxin
    Xu, Xingxiang
    Chen, Zhang
    Peng, Liping
    Ma, Zhuang
    Mo, Biwen
    Li, Chen
    Lv, Yuan
    Zhao, Li
    Zhu, Guangfa
    He, Yong
    Liu, Hua
    Chen, Jichao
    Wang, Ying
    Liang, Yongjie
    Lu, Youjin
    Qin, Zhiqiang
    Yang, Hongzhong
    Zhang, Min
    Wu, Shiman
    Tong, Zhaohui
    Ye, Feng
    Xiao, Zuke
    Wang, Xuefen
    Qiu, Chen
    Kuang, Jiulong
    Huang, Huaping
    Wang, Kai
    Ying, Kejing
    Jin, Faguang
    Lv, Xiaoju
    Huang, Yijiang
    Liu, Deling
    Wang, Wei
    Zhang, Yingyuan
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 64 (02)
  • [37] Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase (vol 8, pg 762, 2020)
    Pivonello, R.
    Fleseriu, M.
    Newell-Price, J.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (09): : e4 - e4
  • [38] Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study
    De Cock, Valerie Cochen
    Dodet, Pauline
    Leu-Semenescu, Smaranda
    Aerts, Cecile
    Castelnovo, Giovanni
    Abril, Beatriz
    Drapier, Sophie
    Olivet, Helene
    Corbille, Anne-Gaelle
    Leclair-Visonneau, Laurene
    Sallansonnet-Froment, Magali
    Lebouteux, Marie
    Anheim, Mathieu
    Ruppert, Elisabeth
    Vitello, Nicolas
    Eusebio, Alexandre
    Lambert, Isabelle
    Marques, Ana
    Fantini, Maria Livia
    Devos, David
    Monaca, Christelle
    Benard-Serre, Nicolas
    Lacombe, Sandy
    Vidailhet, Marie
    Arnulf, Isabelle
    Doulazmi, Mohamed
    Roze, Emmanuel
    LANCET NEUROLOGY, 2022, 21 (05): : 428 - 437
  • [39] Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial
    LeWitt, Peter A.
    Hauser, Robert A.
    Pahwa, Rajesh
    Isaacson, Stuart H.
    Fernandez, Hubert H.
    Lew, Mark
    Saint-Hilaire, Marie
    Pourcher, Emmanuelle
    Lopez-Manzanares, Lydia
    Waters, Cheryl
    Rudzinska, Monika
    Sedkov, Alexander
    Batycky, Richard
    Oh, Charles
    LANCET NEUROLOGY, 2019, 18 (02): : 145 - 154
  • [40] Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
    Giladi, Nir
    Alcalay, Roy N.
    Cutter, Gary
    Gasser, Thomas
    Gurevich, Tanya
    Hoeglinger, Guenter U.
    Marek, Kenneth
    Pacchetti, Claudio
    Schapira, Anthony H., V
    Scherzer, Clemens R.
    Simuni, Tanya
    Minini, Pascal
    Sardi, S. Pablo
    Peterschmitt, M. Judith
    LANCET NEUROLOGY, 2023, 22 (08): : 661 - 671
12345